Physician profile
Deep P Patel
NPI 1194247072
$6,690.78
in general payments reported to CMS, 2019-2025
23 companies · $2,140 in 2025
The $2,140 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $371 · 2022: $753 · 2023: $1,515 · 2024: $1,912 · 2025: $2,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,416 · Education: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,416.36 |
| Education | $150.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $969.22 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $932.02 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $758.17 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $693.26 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $501.62 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $472.27 | 2022-2025 | Spravato, Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $435.47 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $399.45 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $376.06 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $286.65 | 2023-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $197.46 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $166.59 | 2021-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $105.37 | 2023-2025 | Trintellix |
| Corium, LLC | $90.53 | 2023 | Azstarys |
| Tris Pharma INC | $77.26 | 2023-2025 | Dyanavel Xr |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $47.68 | 2021 | |
| Almatica Pharma LLC | $47.02 | 2024 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $40.89 | 2023-2024 | Quviviq |
| Janssen Scientific Affairs, LLC | $24.58 | 2023 | Spravato |
| Noven Therapeutics, LLC | $22.47 | 2024 | Secuado |
| Axsome Therapeutics, INC. | $17.97 | 2023 | Auvelity |
| Collegium Pharmaceutical, INC. | $15.37 | 2025 | Jornay Pm |
| Eisai INC. | $13.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deep Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.